FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

| STATEMENT | OF CHANGES | IN BENEFICIAL | OWNERSHIP |
|-----------|------------|---------------|-----------|
| | | | |

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|--|
| OMB Number: 3235-02 | | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | | |

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT O
STATEMENT O
Filed pursua

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Dayno Jeffrey M. | | | | <u>H</u> | 2. Issuer Name and Ticker or Trading Symbol Harmony Biosciences Holdings, Inc. [HRMY] | | | | | | | | 5. Relationship of Report (Check all applicable) Director X Officer (give title | | | 10% Owner Other (specify | | vner | |
|--|--|--|--|---|---|---|-----|--|------------------|--|--------------------|--|--|--------------------|--|---|----|--|---------------------------------------|
| (Last) 630 W. C | ` | own PIKE, SU | (Middle) ITE 21 | | | 3. Date of Earliest Transaction (Month/Day/Year) 09/07/2021 | | | | | | | | | Chief Medical Officer | | | | |
| (Street) PLYMOUMEETIN | - P/ | A | 19462 | | 4. | 4. If Amendment, Date of Origina | | | | | led (Month/Da | | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | n | |
| (City) | (S | tate) | (Zip) | | | | | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye | | | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an | | | Benefic | | ies For ially (D) Following (I) (| | n: Direct r Indirect istr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | | Transac | saction(s) . 3 and 4) | | | (3 4) |
| Common Stock 09/07/202 | | | 2021 | 21 | | | M | | 10,000 | A | \$8.2 | \$8.22 | | 10,000 | | D | | | |
| Common | Stock | | | 09/07/2 | 2021 | 21 | | | S ⁽¹⁾ | | 10,000 | D | \$37.57 | '83 ⁽²⁾ | 0 | | | D | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year | | | Transaction Code (Instr. | | Exp | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4) | | D S | Price of erivative ecurity nstr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) |
| | | | | | Code | v | (A) | (D) | Date Exerc | isable | Expiration Date | Title | Amou or Numb of Share | er | | | | | |
| Stock Option | \$8.22 | 09/07/2021 | | | M | | | 10,000 | (3 | 3) | 11/13/2027 | Common Stock | ¹ 10,00 | 00 | \$0.00 | 73,469 |) | D | |

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$37.50 to \$37.78. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021.

Remarks:

/s/ Christian Ulrich, Attorneyin-fact 09/09/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.